News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
7,362 Results
Type
Article (1607)
Company Profile (2)
Press Release (5753)
Section
Business (2355)
Career Advice (52)
Deals (499)
Drug Delivery (9)
Drug Development (1470)
Employer Resources (15)
FDA (263)
Job Trends (463)
News (4338)
Policy (487)
Tag
Academia (37)
Alliances (517)
Alzheimer's disease (25)
Antibody-drug conjugate (ADC) (5)
Approvals (259)
Artificial intelligence (7)
Best Places to Work (390)
Biosimilars (39)
Cancer (23)
Career advice (42)
Cell therapy (5)
Clinical research (1186)
Collaboration (9)
COVID-19 (51)
Data (20)
Denatured (4)
Diagnostics (32)
Diversity, equity & inclusion (3)
Drug discovery (3)
Drug pricing (13)
Earnings (836)
Employer branding (7)
Employer resources (12)
Events (1059)
Executive appointments (9)
FDA (268)
Funding (8)
Gene therapy (7)
GLP-1 (35)
Government (113)
Healthcare (130)
Immunology and inflammation (5)
Infectious disease (51)
Inflammatory bowel disease (9)
Interviews (6)
IPO (216)
IRA (5)
Job creations (85)
Job search strategy (41)
Layoffs (18)
Legal (128)
Lung cancer (3)
Lymphoma (9)
Medical device (37)
Medtech (37)
Mergers & acquisitions (289)
Metabolic disorders (8)
Neuroscience (47)
NextGen Class of 2024 (104)
Non-profit (38)
Northern California (30)
Now hiring (19)
Obesity (5)
Opinion (14)
Ovarian cancer (5)
Parkinson's disease (8)
Patents (7)
People (815)
Pharmacy benefit managers (4)
Phase I (356)
Phase II (457)
Phase III (637)
Pipeline (8)
Podcasts (9)
Policy (7)
Postmarket research (24)
Preclinical (83)
Rare diseases (4)
Real estate (52)
Recruiting (8)
Regulatory (292)
Research institute (43)
Resumes & cover letters (5)
Schizophrenia (13)
Series A (3)
Southern California (36)
Startups (63)
The Weekly (5)
United States (187)
Vaccines (4)
Venture capitalists (4)
Weight loss (5)
Date
Last 7 days (9)
Last 30 days (58)
Last 365 days (708)
2024 (658)
2023 (610)
2022 (1063)
2021 (915)
2020 (764)
2019 (681)
2018 (550)
2017 (526)
2016 (501)
2015 (553)
2014 (325)
2013 (184)
2012 (29)
2011 (3)
Location
Africa (25)
Asia (393)
Australia (46)
California (71)
Canada (16)
Connecticut (4)
Europe (1214)
Florida (3)
Illinois (37)
Japan (3)
Maryland (3)
Massachusetts (37)
New Jersey (14)
New York (6)
Northern California (30)
Pennsylvania (8)
South America (27)
Southern California (36)
7,362 Results for "abbvie".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Editorial
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is ‘sole muscarinic winner.’
November 18, 2024
·
5 min read
·
Heather McKenzie
Schizophrenia
AbbVie Shares Plummet 12% as Cerevel Schizophrenia Asset Fails Phase II Trials
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, which put the drug at the center of expectations.
November 11, 2024
·
4 min read
·
Annalee Armstrong
Earnings
AbbVie Beats Q3 Estimates as Skyrizi, Rinvoq Pick Up Slack for Humira
AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance demonstrated the overall strength of its immunology franchise.
October 31, 2024
·
2 min read
·
Tristan Manalac
Business
AbbVie Doubles Down on Alzheimer’s With $1.4B Aliada Buy
The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel platform engineered for efficient blood-brain barrier transport.
October 28, 2024
·
2 min read
·
Heather McKenzie
Parkinson’s disease
AbbVie’s $8.7B Cerevel Buy Starts to Pay off With Phase III Parkinson’s Win
Results from TEMPO-1, which showed that tavapadon significantly improved motor symptoms in patients with Parkinson’s disease, will help AbbVie as it builds a regulatory case for the D1/D5 dopamine receptor agonist.
September 27, 2024
·
2 min read
·
Tristan Manalac
Business
AbbVie’s Humira Continues to Lose Market Share as Biosimilars Gain Ground: Report
CVS Caremark’s recent decision to take AbbVie’s Humira off its major formularies has caused the blockbuster to lose more market share to biosimilars, according to the latest report from Samsung Bioepis.
July 12, 2024
·
2 min read
·
Tristan Manalac
Regulatory
AbbVie’s Skyrizi Wins EU Nod for Ulcerative Colitis, Helps to Weather Humira Patent Cliff
Friday’s European Commission approval is a boost to AbbVie as the company looks to lean on its immunology assets, including Skyrizi, to soften the blow of Humira’s loss of exclusivity.
July 29, 2024
·
2 min read
·
Tristan Manalac
Podcast
AbbVie’s Surprise Schizophrenia Flop, AstraZeneca’s China Drama, Hope in Huntington’s, More
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an investigation into China exec, the Huntington’s pipeline builds momentum and layoffs continue with Sana Biotechnology and 23andMe.
November 13, 2024
·
1 min read
·
Heather McKenzie
Deals
AbbVie Acquires Celsius Therapeutics
AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease.
June 27, 2024
·
4 min read
Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
AbbVie announced that Robert A. Michael has assumed the role of chief executive officer and has joined AbbVie’s Board of Directors.
July 1, 2024
·
3 min read
1 of 737
Next
